In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1

Biopharmaceutics and Drug Disposition

Volumn 29, Issue 2, 2008, Pages 103-118

  Rochat, Bertrand ^a   Zoete, Vincent ^b   Grosdidier, Aurélien ^b   von Grünigen, Sandrine ^a   Marull, Marc ^a   Michielin, Olivier ^a,b,c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^c National Center of Competence in Research in Molecular Oncology   (Switzerland)

Author keywords

Anticancer agent; Cytochrome P 450; Drug metabolism; Imatinib metabolites; Molecular modeling

Indexed keywords

ABELSON KINASE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; COMPLEMENTARY DNA; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; CYTOCHROME P450 3A4; DRUG METABOLITE; IMATINIB; OXIDOREDUCTASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; COMPUTER MODEL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSFORMATION; ELECTROSPRAY MASS SPECTROMETRY; ENZYME KINETICS; GENE EXPRESSION; GENE OVEREXPRESSION; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MOLECULAR DOCKING; MOLECULAR MODEL; PREDICTION; STEM CELL;

ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CYTOCHROME P-450 CYP1A1; HUMANS; KINETICS; MASS SPECTROMETRY; NEOPLASMS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES;

EID: 42049098091     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.598     Document Type: Article

References (74)

1. Michael M, Doherty MM. Tumoral drug metabolism: overview and its implications for cancer therapy. J Clin Oncol 2005; 23: 205-229.
2. Rochat B. Role of cytochrome p450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 2005; 44: 349-366.
3. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640-2653.
4. Krajinovic M, Labuda D, Mathonnet G, et al. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res 2002; 8: 802-810.
5. Dressman MA, Malinowski R, McLean LA, et al. International Randomized Study of Interferon-alpha versus ST1571 Study Group. Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patient treated with imatinib (ST1571). Clin Cancer Res 2004; 10: 2265-2271.
6. Voso MT, D'Alo F, Gumiero D, Guidi F, Hohaus S, Leone G. The CYP1A1*2a allele is an independent prognostic factor for acute myeloid leukemia. Haematologica 2005; 90: 982-984.
7. McLean LA, Gathmann I, Capdeville R, Polymeropoulos MH, Dressman M. Pharmacogenomics analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin Cancer Res 2004; 10: 155-165.
8. Murray GI, Taylor MC, McFadyen MC, et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997; 57: 3026-3031.
9. Nagai F, Hiyoshi Y, Sugimachi K, Tamura HO. Cytochrome P450 (CYP) expression in human myeloblastic and lymphoid cell lines. Biol Pharm Bull 2002; 25: 383-385.
10. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44: 879-894.
11. Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation. J Pharmacol Exp Ther 2001; 296: 537-541.
12. Bowen DT, Frew ME, Rollinson S, et al. CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication. Blood 2003; 101: 2770-2774.
13. Baron JM, Zwadlo-Klarwasser G, Jugert F, et al. Cytochrome P450 1B1: a major P450 isoenzyme in human blood monocytes and macrophage subsets. Biochem Phamacol 1998; 56: 1105-1110.
14. Spatzenegger M, Horsmans Y, Verbeeck R. CYP1A1 but not CYP1A2 proteins are expressed in human lymphocytes. Pharmacol Toxicol 2000; 86: 242-244.
15. Finnström N, Thörn M, Lööf L, Rane A. Independent pattern of cytochrome P450 gene expression in liver and blood in patients with suspected liver disease. Eur J Clin Pharmacol 2001; 57: 403-409.
16. Kikuta Y, Yamashita Y, Kashiwagi S, Tani K, Okada K, Nakata K. Expression and induction of CYP4F subfamily in human leukocytes and HL60 cells. Biochim Biophys Acta 2004; 1683: 7-15.
17. Kikuta Y, Kusunose E, Kusunose M. Prostaglandin and leukotriene omega-hydroxylases. Prostaglandins Other Lipid Mediat 2002; 68-69: 345-362.
18. Le Quere V, Plee-Gautier E, Potin P, Madec S, Salaun JP. Human CYP4F3s are the main catalysts in the oxidation of fatty acid epoxides. J Lipid Res 2004; 45: 1446-1458.
19. Hashizume T, Imaoka S, Mise M, et al. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Phamacol Exp Ther 2002; 300: 298-304.
20. Marull M, Rochat B. Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple quadrupole and linear ion trap mass spectrometers. J Mass Spectrom 2006; 41: 390-404.
21. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62: 4236-4243.
22. Widmer N, Decosterd LA, Csajka C, et al. Population pharmacokinetics of imatinib in oncologic patients and role of alpha-1-acid glycoprotein. Br J Clin Pharmacol 2006; 62:97-112.
23. Murphy CM, Huestis MA. Liquid chromatographic/electrospray ionization tandem mass spectrometric analysis for the quantification of buprenorphine, norbuprenorphine, buprenorphine-3-beta-D-glucuronide and norbuprenorphine-3-beta-D-glucuronide in human plasma. J Mass Spectrom 2005; 40: 70-74.
24. Sayer H, Quintela O, Marquet P, Dupuy JL, Gaulier JM, Lachatre G. Identification and quantitation of six non-depolarizing neuromuscular blocking agents by LC-MS in biological fluids. J Anal Toxicol 2004; 28: 105-110.
25. Wang P, Jin X, Qi M, Fang L. Liquid chromatography-mass spectrometry method for determination of tetramethylpyrazine and its metabolite in dog plasma. J Chromatogr B Anal Technol Biomed Life Sci 2004; 813: 263-268.
26. MacKerell AD, Bashford D, Bellott M, et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 1998; 102: 3586-3616.
27. Halgren TH. Merck Molecular Force Field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 1996; 17: 490-519.
28. Halgren TH. Merck Molecular Force Field. II. MMFF94 van der waals and electrostatic parameters for intermolecular interactions. J Comput Chem 1996; 17: 520-552.
29. Halgren TH. Merck Molecular Force Field. III. Molecular geometries and vibrational frequencies for MMFF94. J Comput Chem 1996; 17: 553-586.
30. Halgren TH. Merck Molecular Force Field. IV. Conformational energies and geometries for MMFF94. J Comput Chem 1996; 17: 587-615.
31. Halgren TH. Merck Molecular Force Field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules. J Comput Chem 1996; 17: 616-641.
32. Bernstein FC, Koetzle TF, Williams GJ, et al. The protein data bank: a computer-based archival file for macromolecular structures. J Mol Biol 1977; 112: 535-542.
33. Berman HM, Battistuz T, Bhat TN, et al. The protein data bank. Acta Cryst 2002; D58: 899-907.
34. Lee MS Salsbury Jr FR, Brooks III CL. Novel generalized born methods. J Chem Phys 2002; 116: 10 606-10 614.
35. Lee MS, Feig M, Salsbury Jr FR, Brooks CL. New analytic approximation to the standard molecular volume definition and its application to generalized born calculations. J Comput Chem 2003; 24: 1348-1356.
36. Brooks BR, Bruccoleri R, Olafson BD, States DJ, Swaminathan S, Karplus M. CHARMM: a program for macromolecular energy, minimization and dynamics calculations. J Comput Chem 1983; 4: 187-217.
37. Grosdidier A, Zoete V, Michielin O. EADock: docking of small molecules into protein active sites with a multiobjective evolutionary optimization. Proteins 2007; 67. 1010-1025.
38. Laskowski RA. SURFNET: a program for visualizing molecular surfaces, cavities and intermolecular interactions. J Mol Graph 1995; 13: 323-330.
39. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem 2004; 25: 1605-1612.
40. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
41. Food and Drug Administration. Center for drug evaluation and research. Approval package. http://www.fda.-gov/cder/foi/nda/2001/ 21335-Gleevec.htm; Part 1 of Clinical Pharmacology Biopharmaceutics Review (accessed 16/01/2007).
42. Gschwind HP, Pfaar U, Waldmeier F, et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 2005; 33: 1503-1512.
43. Parte P, Kupfer D. Oxidation of tarnoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab Dispos 2005; 33: 1446-1452.
44. Loaiza-Perez AI, Kenney S, Boswell J, et al. Aryl hydrocarbon receptor activation of an antitumor amino-flavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther 2004; 3: 715-725.
45. Larsen JE, Colosimo ML, Yang IA, Bowman R, Zimmerman PV, Fong KM. Risk of non-small cell lung cancer and the cytochrome P4501A1 IIe462Val polymorphism. Cancer Causes Control 2005; 16: 579-585.
46. Cashman JR. The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development. Drug Discov Today 2004; 9: 574-581.
47. Agundez JA. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab 2004; 5: 211-224.
48. Miyoshi Y, Ando A, Takamura Y, Taguchi T, Tamaki Y, Noguchi S. prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer 2002; 97: 129-132.
49. Dhaini HR, Thomas DG, Giordano TJ, et al. Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J Clin Oncol 2003; 21: 2481-2485.
50. Goetz MP, Rae JM, Suman JM, et al. Pharmacogenomic determinants of outcome with tamoxifen therapy: findings from the randomized North Central Cancer Treatment Group adjuvant breast cancer trial 89-30-52. Breast Cancer Res Treat 2004; 88(Suppl 1): S35.
51. DeMichele A, Aplenc R, Botby1 J, et al. Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J Clin Oncol 2005, 23: 5552-5559.
52. Shah NP, Sawyers CL. Mechanisms of resistance to ST1571 in Philadelphia chromosome-associated leukemias. Oncogene 2003; 22: 7389-7395.
53. Antonescu. CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11:4182-4190.
54. Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106:2128-2137.
55. Nimmanapalli R, O'Bryan E, Huang Bali P, et al. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukenmia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2002; 62: 5761-5769.
56. Donato NJ, Wu JY, Stapley JM, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004; 64: 672-677.
57. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004; 104: 2926-2932.
58. Moravcova J, Zmekova V, Klamova H, et al. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase. Leuk Res 2004; 28: 415-419.
59. Barnes DJ, Palaiologou D, Panousopoulou E, et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005; 65: 8912-8919.
60. Van der Kuip H, Moehring A, Wohlbold L, Miething C, Duyster J, Aulitzky WE. Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines. Leuk Res 2004; 28: 405-408.
61. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873-2878.
62. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. Alpha 1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003; 9: 625-632.
63. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739-3745.
64. Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE. hOCT 1 and resistance to imatinib. Blood 2005; 106: 1133-1134.
65. Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401-409.
66. Burger H, van Tol H, Brok M, et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDRI) drug transport pumps. Cancer Biol Ther 2005; 4: 747-752.
67. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267-1270.
68. Elrick LJ, Jorgensen HG, Mountford JC, Holyoake TL. Punish the parent not the progeny. Blood 2005; 105: 1862-1866.
69. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-325.
70. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701-4707.
71. Holtz MS, Bhatia R. Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells. Leuk Lymphoma 2004; 45: 237-245.
72. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85-94.
73. Uchida N, Dykstra B, Lyons K. Leung F, Kristiansen M, Eaves C. ABC transporter activities of murine hematopoietic stem cells vary according to their developmental and activation status. Blood 2004; 103: 4487-4495.
74. Soucek P, Anzenbacher P, Skoumalova I, Dvorak M. Expression of cytochrome P450 genes in CD34+hematopoietic stem and progenitor cells. Stem Cells 2005; 23: 1417-1422.